Log in

Relevant bibliographies by topics / Nepafenac / Journal articles

To see the other types of publications on this topic, follow the link: Nepafenac.

Journal articles on the topic 'Nepafenac'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Nepafenac.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Nepafenac." Reactions Weekly &NA;, no. 1176 (2007): 24. http://dx.doi.org/10.2165/00128415-200711760-00074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Nepafenac." Reactions Weekly &NA;, no. 1197 (2008): 33. http://dx.doi.org/10.2165/00128415-200811970-00113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Nepafenac." Reactions Weekly &NA;, no. 1278 (2009): 22. http://dx.doi.org/10.2165/00128415-200912780-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Abu Hussein, Nahla B., Ahmed A. Mohalhal, Dalia A. Ghalwash, and Ahmed A. Abdel-Kader. "Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients." Journal of Ophthalmology 2017 (2017): 1–5. http://dx.doi.org/10.1155/2017/3765253.

Full text

Abstract:

Purpose. To evaluate effectiveness of topical nepafenac in reducing macular edema following panretinal photocoagulation (PRP). Design. Prospective randomized double-blinded controlled study. Methods. Sixty eyes of 60 patients having proliferative or severe nonproliferative diabetic retinopathy had PRP. Patients were then divided into two groups: nepafenac group (30 eyes) receiving 1% topical nepafenac eye drops for 6 months and control group (30 eyes) receiving carboxymethylcellulose eye drops for 6 months. Best-corrected visual acuity (BCVA) and macular optical coherence tomography were follo

APA, Harvard, Vancouver, ISO, and other styles

5

Saita, Maria Grazia, Fabiola Spitaleri, Katia Mangano, Danilo Aleo та Angela Patti. "Synergic Effect of Methyl-β-Cyclodextrin and Hydrophilic Polymers on Nepafenac Solubilization: Development of a 0.3% Ophthalmic Solution". Molecules 30, № 15 (2025): 3090. https://doi.org/10.3390/molecules30153090.

Full text

Abstract:

Nepafenac is an anti-inflammatory drug used in ophthalmology, marketed as a suspension due to its low aqueous solubility. A solution formulation could provide better bioavailability than suspension and facilitate single unit doses, avoiding the use of preservatives which are required to maintain sterility in multidose packaging. In this study, solubilization of nepafenac was achieved in the presence of randomly methylated β-cyclodextrin (RAMEB) and the actual complexation was assessed by NMR and phase-solubility studies. It was also found that the addition of hydrophilic polymers plays an impo

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Ketorolac/nepafenac." Reactions Weekly &NA;, no. 1184 (2008): 25. http://dx.doi.org/10.2165/00128415-200811840-00076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mirza, Rabbia, Imran Basit, Summaya Khan, Zahid Ullah, Shahid Tarar, and Muhammad Awais. "INHIBITION OF SURGICALLY INDUCED MIOSIS WITH NEPAFENAC." PAFMJ 71, no. 3 (2021): 801–04. http://dx.doi.org/10.51253/pafmj.v71i3.3324.

Full text

Abstract:

Objective: To assess the efficacy of prophylactic administration of 0.1% nepafenac in the maintenance of trans-operative mydriasis following cataract surgery. Study Design: Quasi-experimental study. Place and Duration of Study: Armed Forces Institute of Ophthalmology, Rawalpindi, from Oct 2018 to Mar 2019. Methodology: A total of 70 patients undergoing cataract surgery phacoemulsification were randomly placed in either the control group or the nepafenac group. Nepafenac eye drops were administered as one drop 8 hourly, 3 days before surgery. Control group didn’t receive any m

APA, Harvard, Vancouver, ISO, and other styles

8

Nardi, Marco. "Nepafenac in the Prevention and Treatment of Ocular Inflammation and Pain Following Cataract Surgery and in the Prevention of Post-operative Macular Oedema in Diabetic Patients." European Ophthalmic Review 06, no. 03 (2012): 169. http://dx.doi.org/10.17925/eor.2012.06.03.169.

Full text

Abstract:

Nepafenac ophthalmic suspension is a topical non-steroidal anti-inflammatory drug (NSAID) approved in the US and Europe for prevention and treatment of post-operative pain and inflammation associated with cataract surgery, and recently approved in Europe for reduction in risk of post-operative macular oedema associated with cataract surgery in diabetic patients. Unlike conventional NSAIDs, nepafenac is a prodrug that is uncharged and this results in great corneal permeability. Experimental studies on nepafenac demonstrated enhanced permeability compared with other NSAIDs, and rapid bioactivati

APA, Harvard, Vancouver, ISO, and other styles

9

Jabeen, Saira, Zeeshan Hameed, Bazla Batool, Irfan Qayyum Malik, Aamna Jabran, and Abdullah Younas. "COMPARISON OF EFFICACY OF NEPAFENAC 0.3% AND NEPAFENAC 0.1% TO PREVENT AND CONTROL POSTOPERATIVE PAIN AND CONJUNCTIVAL REDNESS AFTER CATARACT SURGERY: A RANDOMIZED CONTROL TRIAL." Pakistan Postgraduate Medical Journal 32, no. 03 (2022): 110–14. http://dx.doi.org/10.51642/ppmj.v32i03.456.

Full text

Abstract:

Purpose: To compare the efficacy of nepafenac 0.3% with nepafenac 0.1% to control postoperative pain and conjunctival redness after cataract surgery. Study Design: Randomized control trial Place and Duration: Ophthalmology Department, DHQ Teaching Hospital, Gujranwala from November 2020 to January 2021. Materials and Methods: A prospective review of 70 patients operated for age-related cataract was done. Patients were divided into two equal groups. Group A patients were given Ilevro eye drops (nepafenac 0.3%) once a day and group B patients were instilled Nevanac eye drops (n

APA, Harvard, Vancouver, ISO, and other styles

10

Rajnee, Sinha, and Priyanka. "Prospective, Comparative Assessment of Safety and Efficacy of Various Nsaids with Prednisolone Acetate After Uneventful Phacoemulsification." International Journal of Pharmaceutical and Clinical Research 14, no. 2 (2022): 513–23. https://doi.org/10.5281/zenodo.13857242.

Full text

Abstract:

<strong>Aim:</strong> A comparative analysis of topical corticosteroids and non-steroidal anti-inflammatory drugs to control inflammation and macular edema following uneventful phacoemulsification. <strong>Methods: </strong>This prospective, comparative study conducted in the Department of Ophthalmology, Patna Medical College and Hospital, Patna, Bihar, India, for 12 months.  This study comparing nepafenac (0.1%), bromfenac (0.07%), preservative-free ketorolac (0.4%), nepafenac (0.3%), and prednisolone acetate (1%) eye drops in patients undergoing uncomplicated phacoemulsif

APA, Harvard, Vancouver, ISO, and other styles

11

Uddin, Salah, and Haroon Rashid. "A Comparison of Topical Nepafenac with Ketorolac Tromethamine in Maintaining Pupilary Dilatation during Phacoemulsification." Journal of Saidu Medical College, Swat 12, no. 1 (2022): 11–15. http://dx.doi.org/10.52206/jsmc.2022.12.1.552.

Full text

Abstract:

Background: The standard surgical procedure for cataract surgery now a days is phacoemulsification with intraocular lens (IOL) implantation, that gives excellent visual results. Stable and adequate mydriasis is equired throughout phacoemulsification surgery. Intraoperative pupil Constriction (miosis) is associated with an increased risk of intraoperative complications especially in difficult cases and it can result in prolonged surgical time. Objective: To compare the effectiveness of prophylactic administration of topical ketorolac tromethamine 0.5% and nepafenac 0.1% on maintaining myd

APA, Harvard, Vancouver, ISO, and other styles

12

Prakash, Sanjana, Basavaraj Bhandare, Satyanarayana V., and Kaushal Kumar. "A comparative study on efficacy of nepafenac and flurbiprofen in maintenance of intraoperative mydriasis during cataract surgery: an open label randomized controlled trial." International Journal of Basic & Clinical Pharmacology 7, no. 4 (2018): 617. http://dx.doi.org/10.18203/2319-2003.ijbcp20181002.

Full text

Abstract:

Background: Surgery on the ocular tissue brings about activation of phospholipase A3 thereby releasing prostaglandins and leukotrienes. Prostaglandins bring about meiosis during surgery, changes in IOP, conjunctival hyperaemia. Newer topical NSAID’s Nepafenac and Flurbiprofen are potent inhibitors of the cyclooxygenase enzyme thereby inhibiting the biosynthesis of prostaglandins. Objective of this study was to compare the efficacy of preoperative use of topical Nepafenac (0.1%) and Flurbiprofen (0.03%) in maintenance of intraoperative mydriasis during cataract surgery.Methods: A randomised, co

APA, Harvard, Vancouver, ISO, and other styles

13

Bikbov, M. M., E. L. Usubov, G. M. Kazakbayeva, et al. "Assessment of anti-inflammatory therapy effectiveness in the early postoperative period of cataract surgery." Russian Ophthalmological Journal 17, no. 1 (2024): 20–27. http://dx.doi.org/10.21516/2072-0076-2024-17-1-20-27.

Full text

Abstract:

Purpose: To evaluate the efficacy and safety of nonsteroid anti-inflammatory drugs (NSAIDs) in monotherapy and as part of combination therapy with glucocorticosteroids for the prevention of postoperative inflammation after cataract phacoemulsification.Material and methods. The study included 75 patients who underwent phacoemulsification with implantation of a posterior chamber intraocular lens. Patients were divided into groups depending on anti-inflammatory treatment: A1 — nepafenac (Nepafenac-Optic), A2 — bromfenac (Broxinac), A3 — dexamethasone (Dexamethasone), B1 — Nepafenac-Optic + dexame

APA, Harvard, Vancouver, ISO, and other styles

14

Memon, Zulfiqar Ahmed, Omar Zafar, Arsalan Farooq, Shabnam Memon, Najam ul Hassan, and M. Tahir Shah. "CATARACT SURGERY;." Professional Medical Journal 24, no. 12 (2017): 1812–17. http://dx.doi.org/10.29309/tpmj/2017.24.12.561.

Full text

Abstract:

Objectives: To determine the efficacy of topical nepafenac 0.1% eye dropsas compared toprednisolone acetate 1% eye drops in the management of postoperativeinflammation after cataract surgery. Study Design: Randomized controlled clinical study.Place and Duration of study: Pakistan air force hospital Rafiqui from Oct 2016 to Feb 2017.Patients and methods: Two hundred and forty eight eyes were randomly divided in two equalgroups. Patients received nepafenac 0.1% or prednisolone acetate 1% as single drop 8 hourlybeginning 1 day preoperatively, continued till 2 weeks post-operatively. Efficacy of t

APA, Harvard, Vancouver, ISO, and other styles

15

Lorenzo-Veiga, Blanca, Patricia Diaz-Rodriguez, Carmen Alvarez-Lorenzo, Thorsteinn Loftsson, and Hakon Hrafn Sigurdsson. "In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation." Nanomaterials 10, no. 4 (2020): 709. http://dx.doi.org/10.3390/nano10040709.

Full text

Abstract:

The aim of this study was to design and evaluate novel cyclodextrin (CD)-based aggregate formulations to efficiently deliver nepafenac topically to the eye structure, to treat inflammation and increase nepafenac levels in the posterior segment, thus attenuating the response of inflammatory mediators. The physicochemical properties of nine aggregate formulations containing nepafenac/γ-CD/hydroxypropyl-β (HPβ)-CD complexes as well as their rheological properties, mucoadhesion, ocular irritancy, corneal and scleral permeability, and anti-inflammatory activity were investigated in detail. The resu

APA, Harvard, Vancouver, ISO, and other styles

16

Şahin, Asena Keleş, Fatih Ulaş, and Ümit Doğan. "Effect of nepafenac 0.1% on retinal thickness after cataract surgery in patients without risk factors for cystoid macular edema." International Journal of Ophthalmology 13, no. 12 (2020): 1901–7. http://dx.doi.org/10.18240/ijo.2020.12.09.

Full text

Abstract:

AIM: To evaluate the effect of topical preoperative nepafenac 0.1% treatment on postoperative macular edema using optical coherence tomography (OCT) after uncomplicated cataract surgery. METHODS: Ninety eyes of 90 patients without any risk factors were included in the study. The patients were assigned to three groups: group 1, treated with topical prednisolone acetate 1%; group 2, treated with topical nepafenac 0.1% in addition to prednisolone acetate (1%); and group 3, those who started receiving nepafenac 0.1% treatment 3d prior to surgery and continued the treatment postoperatively in addit

APA, Harvard, Vancouver, ISO, and other styles

17

Micheal Thamin Sabbagh, Mahamoud Rajab, Kahtan Jalloul, Micheal Thamin Sabbagh, Mahamoud Rajab, Kahtan Jalloul. "Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2: دراسة فعالية إضافة قطرة النيبافيناك الموضعي 0.1% في زيادة توسع الحدقة لدى مرضى الداء السكري النمط 2". Journal of medical and pharmaceutical sciences 6, № 1 (2022): 74–81. http://dx.doi.org/10.26389/ajsrp.l140821.

Full text

Abstract:

Objective: To evaluate the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with Diabetes Mellitus type 2. Methods: the study was conducted on 73 eyes of 73 patients who had type 2 diabetes for 5 years or more. The pupil diameter (PD) was measured in the both eyes without dilation using an Autorefractokeratometer (Grand Seiko\GR- 3500 Ka), then the pupils were dilated in the both eyes using topical Tropicamide 1%. A second measurement of (PD) was taken after dilating using the same device. Topical Nepafenac 0.1% were prescribed 3 times a day for 3 days in th

APA, Harvard, Vancouver, ISO, and other styles

18

Nuraita, Ika, Retno Ekantini, Rinanto Prabowo, Suhardjo Pawiroranu, Agus Supartoto, and Indra Tri Mahayana. "Differences in pain and inflammation between Diclofenac 0.1% and Nepafenac 0.1% after cataract surgery." International Eye Research 1, no. 4 (2020): 224–28. http://dx.doi.org/10.18240/ier.2020.04.04.

Full text

Abstract:

AIM: To compare pain level and inflammation between preoperative topical Diclofenac 0.1% and Nepafenac 0.1% in patients undergoing cataract surgery. METHODS: This research was designed as prospective randomized clinical trial and conducted in June to August 2017 at Dr. Yap Eye Hospital. There were 56 subjects underwent phacoemulsification operation (single operator) and diagnosed as senile cataract and no adverse events were found. Subjects were divided into 2 groups according to preoperative eye drop medication, namely Diclofenac group and Nepafenac group. Participants and phaco-surgeon were

APA, Harvard, Vancouver, ISO, and other styles

19

Mohamed-Noriega, Karim, Karla Butrón-Valdez, Jeronimo Vazquez-Galvan, Jibran Mohamed-Noriega, Humberto Cavazos-Adame, and Jesús Mohamed-Hamsho. "Corneal Melting after Collagen Cross-Linking for Keratoconus in a Thin Cornea of a Diabetic Patient Treated with Topical Nepafenac: A Case Report with a Literature Review." Case Reports in Ophthalmology 7, no. 1 (2016): 119–24. http://dx.doi.org/10.1159/000444437.

Full text

Abstract:

Purpose: To report the case of a 50-year-old woman with diabetes that presented with corneal melting and perforation 6 weeks after collagen cross-linking (CxL) for keratoconus (KC) and postoperative use of nepafenac eye drops, a nonsteroidal anti-inflammatory drug (NSAID). Methods: This is a case report of a patient with diabetes, KC and a thin cornea that had undergone left eye corneal CxL at a different hospital followed by postoperative use of nepafenac eye drops for 6 weeks. Results: The patient presented for the first time to our clinic with left corneal melting, perforation and iris prol

APA, Harvard, Vancouver, ISO, and other styles

20

Wolf, Eric Jay, Lynda Z. Kleiman, and Amilia Schrier. "Nepafenac-associated corneal melt." Journal of Cataract & Refractive Surgery 33, no. 11 (2007): 1974–75. http://dx.doi.org/10.1016/j.jcrs.2007.06.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Jain, Vatika, A. Anuradha, Nishat Sultana, Kavnit Kaur, and M. Vidyadevi. "Epitheliopathy post topical nepafenac." Indian Journal of Ophthalmology - Case Reports 3, no. 3 (2023): 892. http://dx.doi.org/10.4103/ijo.ijo_3110_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bhatt, Riddhi, Mayuri Gurjar, Alpa Gor, and Bharat Gajjar. "A Case Report: Nepafenac Eye Drops induced Unilateral Corneal Melt." Journal of Health Sciences and Professions Education 1, no. 1 (2021): 34. https://doi.org/10.5455/jhspe.20210610092308.

Full text

Abstract:

This case report gives the details of a 46-year-old female, who developed a rare & severe side effect unilateral left sided corneal melt with the use of Nepafenac 0.1% eyedrops, which had been chronically used in both the eyes by her for retinitis pigmentosa. Prolonged use of Nepafenac, a nonsteroidal anti-inflammatory drug or the altered pH of the eyedrops can be the contributing factors for such severe side effect.

APA, Harvard, Vancouver, ISO, and other styles

23

Malik, VK, Sonali Singh, KPS Malik, et al. "A Comparative Study of Topical Dexamethasone 0.1% and Topical Nepafenac 0.1% Ophthalmic Solutions in Cataract Patients Undergoing Manual Small Incision Cataract Surgery." Delhi Journal of Ophthalmology 22, no. 3 (2012): 183–86. https://doi.org/10.4103/0972-0200.376589.

Full text

Abstract:

Aim: To study the effect of topical dexamethasone 0.1% and topical nepafenac 0.1% ophthalmic solutions in cataract patients, undergoing manual small incision cataract surgery. Method: The effect of nepafenac 0.1% following cataract surgery was studied and compared to routine corticosteroid, dexamethasone 0.1% in a randomized prospective clinical trial. Both groups were similar in baseline parameters. Postoperative inflammatory response, intraocular pressure, corneal thickness following manual small incision cataract extraction were assessed in both groups in the initial 8 weeks and the severit

APA, Harvard, Vancouver, ISO, and other styles

24

Lane, Stephen S. "Nepafenac: A Unique Nonsteroidal Prodrug." International Ophthalmology Clinics 46, no. 4 (2006): 13–20. http://dx.doi.org/10.1097/01.iio.0000212129.53019.49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Takahashi, Kyoichi, Yoshitsugu Saishin, Yumiko Saishin, et al. "Topical Nepafenac Inhibits Ocular Neovascularization." Investigative Opthalmology & Visual Science 44, no. 1 (2003): 409. http://dx.doi.org/10.1167/iovs.02-0346.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Schoenberger, Scott D., Daniel M. Miller, Michael R. Petersen, Robert E. Foster, Christopher D. Riemann, and Robert A. Sisk. "Nepafenac for Epiretinal Membrane Surgery." Ophthalmology 118, no. 7 (2011): 1482.e1–1482.e3. http://dx.doi.org/10.1016/j.ophtha.2011.01.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ulrich, J. Niklas. "TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION." Retina 34, no. 3 (2014): 509–11. http://dx.doi.org/10.1097/iae.0b013e3182a0e611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ozer, Omer, and Muhammet Latif Tuncer. "Add-on therapy with different non-steroidal anti-inflammatory agents in the management of non-infectious, non-necrotizing episcleritis." Medical hypothesis, discovery & innovation in optometry 2, no. 4 (2022): 133–37. http://dx.doi.org/10.51329/mehdioptometry137.

Full text

Abstract:

Background: Episcleritis is a common ocular inflammatory disease that can cause red eye. It is usually managed using single or combined topical corticosteroids and topical or oral non-steroidal anti-inflammatory drugs (NSAIDs) as directed by clinical response. However, recurrence is possible. This study aimed to compare the effects of add-on therapies using different topical NSAIDs in the management of treatment-naive, non-infectious, non-necrotizing episcleritis. Methods: Seventy-five eyes of 75 patients with non-infectious, non-necrotizing unilateral episcleritis were included in this

APA, Harvard, Vancouver, ISO, and other styles

29

Ogurel, Tevfik, Reyhan Ogurel, Fatma Ozkal, Yaşar Ölmez, Nurgül Örnek, and Zafer Onaran. "Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection." Therapeutic Advances in Ophthalmology 11 (January 2019): 251584141986185. http://dx.doi.org/10.1177/2515841419861856.

Full text

Abstract:

Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 pat

APA, Harvard, Vancouver, ISO, and other styles

30

Yani, E. V., E. N. Orlova, and V. A. Golikova. "Antiinflammatory therapy of neurotrophic corneal diseases." Russian Ophthalmological Journal 12, no. 4 (2019): 77–82. http://dx.doi.org/10.21516/2072-0076-2019-12-4-77-82.

Full text

Abstract:

Clinical data on new directions in combined treatment of neurotrophic keratitis, including anti-inflammatory therapy are presented.Purpose. To compare the effectiveness of bromfenac 0.09 %, nepafenac 0.1 % and indomethacin 0.1 % eye drops in the treatment of neurotrophic keratitis (NK).Materials and methods. 22 NK patients, aged 34 to 78, were divided into three groups. Group I received bromfenac 0.09 %, group II, nepafenac 0.1 %, and group III, indomethacin 0.1 %. Ophthalmic tests included visometry, biomicroscopy, corneal sensitivity determination, as well as diagnostic tests to determine in

APA, Harvard, Vancouver, ISO, and other styles

31

Bhosale, Pramod Motiram, and Manmeet Singh. ""Optimizing Pharmaceutical Formulations: Advancements in Nanosuspension Pre-Formulation to Enhance Solubility and Bioavailability of Active Agents"." International Journal of Membrane Science and Technology 10, no. 5 (2023): 804–12. http://dx.doi.org/10.15379/ijmst.v10i5.3546.

Full text

Abstract:

This study aimed to enhance the bioavailability of a poorly water soluble drug by developing a nanosuspension through an innovative formulation method. The nanosuspension was produced with meticulous attention to the materials reliability and excellent quality. Nepafenac was characterised in the pre-formulation study by establishing its melting point, solubility in different solvents, organoleptic properties, and creating a calibration curve. We utilised UV spectroscopy to determine the maximum wavelength (?max) of Nepafenac and construct a standard calibration curve in ethanol. To ensure the

APA, Harvard, Vancouver, ISO, and other styles

32

Afrashi, Filiz, Arzu Seyhan Karatepe Hashas, Cahit Shahbazov, et al. "Reliability of Intravitreal Nepafenac in Rabbits." Journal of Ocular Pharmacology and Therapeutics 31, no. 1 (2015): 43–50. http://dx.doi.org/10.1089/jop.2014.0053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

McCulley, James P. "Ketorolac versus nepafenac in cataract surgery." Journal of Cataract & Refractive Surgery 34, no. 3 (2008): 345–46. http://dx.doi.org/10.1016/j.jcrs.2007.11.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Aaronson, Alexander, Asaf Achiron, and Raimo Tuuminen. "Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac." Journal of Clinical Medicine 9, no. 9 (2020): 3034. http://dx.doi.org/10.3390/jcm9093034.

Full text

Abstract:

Background: To evaluate the clinical course of pseudophakic cystoid macular edema (PCME) treated with topical non-steroidal anti-inflammatory drugs (NSAIDs). Methods: An analysis of the clinical course of PCME consisting of 536 eyes of 536 patients from five consecutive randomized clinical trials aimed at the optimization of anti-inflammatory medication in patients undergoing routine cataract surgery. PCME was classified as (i) grade 0a; no macular thickening, (ii) grade 0b; macular thickening (central subfield macular thickness (CSMT) increase of at least 10%) without signs of macular edema,

APA, Harvard, Vancouver, ISO, and other styles

35

Duong, Hon-Vu Quang, Kenneth C. Westfield, and Thomas H. Chalkley. "Reply: Ketorolac versus nepafenac in cataract surgery." Journal of Cataract & Refractive Surgery 34, no. 3 (2008): 346. http://dx.doi.org/10.1016/j.jcrs.2007.11.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hussar, Daniel A. "New Drugs: Ramelteon, Tipranavir, Nepafenac, and Deferasirox." Journal of the American Pharmacists Association 46, no. 1 (2006): 107–11. http://dx.doi.org/10.1331/154434506775268643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Yoon, Michael K., Ayman Naseri, Travis Porco, and Stephen D. McLeod. "Nepafenac-assisted mydriasis in a rabbit model." Journal of Cataract & Refractive Surgery 36, no. 10 (2010): 1779–82. http://dx.doi.org/10.1016/j.jcrs.2010.04.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Yu, Shihui, Guoxin Tan, Dandan Liu, Xinggang Yang, and Weisan Pan. "Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies." RSC Advances 7, no. 35 (2017): 21475. http://dx.doi.org/10.1039/c7ra90048a.

Full text

Abstract:

Correction for ‘Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies’ by Shihui Yu et al., RSC Adv., 2017, 7, 16668–16677.

APA, Harvard, Vancouver, ISO, and other styles

39

Saurabh, Kumar, Rupak Roy, Debmalya Das, and Aneesha Lobo. "Eyelid excoriation and erythema with nepafenac eye drop." Indian Dermatology Online Journal 7, no. 4 (2016): 323. http://dx.doi.org/10.4103/2229-5178.185478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Tapia Quijada, H. E., E. Quijada Fumero, F. I. Mesa Lugo, M. Serrano García, and N. Betancor Caro. "Nepafenac for cystoid macular oedema secondary to paclitaxel." Archivos de la Sociedad Española de Oftalmología (English Edition) 96, no. 8 (2021): 434–37. http://dx.doi.org/10.1016/j.oftale.2020.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Margulis, Andrea V., Eline Houben, Jesper Hallas, et al. "Ophthalmic nepafenac use in the Netherlands and Denmark." Acta Ophthalmologica 95, no. 5 (2017): 509–17. http://dx.doi.org/10.1111/aos.13468.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Achiron, Asaf, Lily Karmona, Michael Mimouni, et al. "Comparison of the Tolerability of Diclofenac and Nepafenac." Journal of Ocular Pharmacology and Therapeutics 32, no. 9 (2016): 601–5. http://dx.doi.org/10.1089/jop.2016.0057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Jha, Ramesh, Vismapratap Sur, Arnab Bhattacharjee, et al. "Intracameral Use of Nepafenac: Safety and Efficacy Study." Current Eye Research 43, no. 5 (2017): 630–38. http://dx.doi.org/10.1080/02713683.2017.1408129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Shelley, Haley, Makenzie Grant, Forrest T. Smith, Eva M. Abarca, and R. Jayachandra Babu. "Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation." AAPS PharmSciTech 19, no. 6 (2018): 2554–63. http://dx.doi.org/10.1208/s12249-018-1094-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Feiz, Vahid, Thomas J. Oberg, Christopher J. Kurz, Nick Mamalis, and Majid Moshirfar. "Nepafenac-associated Bilateral Corneal Melt After Photorefractive Keratectomy." Cornea 28, no. 8 (2009): 948–50. http://dx.doi.org/10.1097/ico.0b013e318199e9cc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Panigrahi, Pradeep Kumar. "Prophylactic topical nepafenac in preventing postoperative macular edema." Oman Journal of Ophthalmology 18, no. 1 (2025): 104–5. https://doi.org/10.4103/ojo.ojo_341_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Singh, Vikas, and K. Saravanan. "Development and validation of in vitro release test for a BCS class 4 drug nepafenac ophthalmic suspension using USP apparatus IV." International Journal of Research in Pharmaceutical Sciences 16, no. 1 (2025): 103–10. https://doi.org/10.26452/ijrps.v16i1.4743.

Full text

Abstract:

The objective of the present study was to develop and validate an in vitro release test for Nepafenac ophthalmic suspension using a USP Type IV apparatus. Nepafenac is an approved drug for treating postoperative ocular inflammation and pain following cataract surgery. Various conditions, including the type and volume of dissolution medium, filter type, sample weight, and flow rate, were evaluated. The optimal in vitro dissolution profile was achieved using Apparatus IV (open-loop), STF (pH 7.4) as the dissolution medium, a GF/D membrane filter, and 0.5 g of the sample with a medium flow rate o

APA, Harvard, Vancouver, ISO, and other styles

48

Anoop, L., B. N. Viswanath, S. Shashidhar, Ravi Bypareddy, R. H. Hithashree, and S. Surabhi. "Role of nonsteroidal anti-inflammatory drugs on change in macular volume postcataract surgery in diabetic eyes: A retrospective comparative study." Oman Journal of Ophthalmology 17, no. 2 (2024): 187–91. http://dx.doi.org/10.4103/ojo.ojo_26_23.

Full text

Abstract:

CONTEXT: Diabetic eyes suffer from variety of complications including macular edema. Cataract surgery is the most commonly done procedure throughout the world and majority would be diabetics. As pseudophakic-cystoid macular edema (CME) is a known complication following cataract surgery, our study concentrated on finding the role of prophylactic topical nonsteroidal anti-inflammatory drugs (NSAIDs) on change in total macular volume (TMV) postcataract surgery in diabetic eyes. AIMS: To evaluate the role of NSAIDs on change in TMV postcataract surgery in diabetic eyes. SETTINGS AND DESIGN: Retros

APA, Harvard, Vancouver, ISO, and other styles

49

Bottós, Juliana Mantovani, Michel Eid Farah, Ana Luisa Höfling-Lima, and Fabio Bom Aggio. "Pharmacology, clinical efficacy and safety of nepafenac ophthalmic suspension." Expert Review of Ophthalmology 3, no. 2 (2008): 131–38. http://dx.doi.org/10.1586/17469899.3.2.131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Nepafenac* controls pain and postoperative inflammation following cataract surgery,." Inpharma Weekly &NA;, no. 1484 (2005): 10. http://dx.doi.org/10.2165/00128413-200514840-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!